Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Set Earlier-than-FY2020 Date for 80% Generic Target: Govt Working Group
A working group under the government’s administrative reform panel has compiled an interim report on generic promotions, calling for setting a deadline earlier than the health ministry-envisioned FY2020 to achieve a generic penetration rate of at least 80%. The working…
To read the full story
Related Article
- Govt Working Group Calls for Switching Contract Manufacturing of Long-Listed Drugs to Generic Production
June 16, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- JPMA Says Generic Target Has Huge Impact on Innovation, Balanced Approach Needed
June 1, 2015
- Considerable Resolve Needed for Proposed 80% Generic Target: JGA
May 25, 2015
- Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015
- Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion
May 12, 2015
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…